Related Experiment Video

Updated: Jul 27, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

17.8K

LEM Domain Containing 1 Acts as a Novel Oncogene and Therapeutic Target for Triple-Negative Breast Cancer

Xiangling Li1,2, Shilong Jiang3, Ting Jiang1

  • 1Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.

Cancers
|June 10, 2023
PubMed

Insights

LEMD1 is highly expressed in triple-negative breast cancer (TNBC), contributing to poor survival. Targeting LEMD1 shows promise for improving TNBC treatment and chemotherapy efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to limited therapeutic options and poor patient survival rates.
  • Identifying novel therapeutic targets is crucial for advancing TNBC treatment strategies.

Purpose of the Study:

  • To investigate the role of LEM domain containing 1 (LEMD1) as a potential therapeutic target in triple-negative breast cancer.
  • To elucidate the mechanism by which LEMD1 influences TNBC progression and patient outcomes.

Main Methods:

  • Bioinformatic analysis of public databases and patient samples to assess LEMD1 expression in TNBC.
  • In vitro studies involving LEMD1 silencing to evaluate its impact on TNBC cell proliferation and migration.
  • In vivo tumor formation assays and chemosensitivity tests to assess the therapeutic potential of targeting LEMD1.

Main Results:

  • LEMD1 was found to be highly expressed in TNBC tissues and correlated with reduced patient survival.
  • LEMD1 silencing significantly inhibited TNBC cell proliferation, migration, and in vivo tumor growth.
  • Knockdown of LEMD1 increased the sensitivity of TNBC cells to paclitaxel chemotherapy.
  • LEMD1 promotes TNBC progression by activating the ERK signaling pathway.

Conclusions:

  • LEMD1 functions as a novel oncogene in triple-negative breast cancer.
  • Targeting LEMD1 represents a promising therapeutic strategy to improve treatment outcomes and enhance chemotherapy efficacy in TNBC.
Keywords:
ERKLEMD1TNBCtherapeutic target

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.2K